5466940-POS-800937-06C.indd

AACC 2017 -- Alzheimer's disease (AD) is the most common neurodegenerative disorder and is a major health problem among older people. Synaptic dysfunction and loss are directly linked to memory disturbances and other cognitive symptoms that are present at the early stages of AD. The synaptic loss occurs early and it correlates with cognitive deficits in patients with AD. Therefore, the measurement of synapse proteins in CSF could be useful for studies of disease mechanism, to improve tools for early diagnosis and prognosis, and to monitor drug effects on synaptic degeneration in clinical trials of disease modifying therapies for AD. The postsynaptic protein Neurogranin in CSF has been reported to increase in AD, including pre-dementia stage of disease, making it a promising CSF biomarker.